Effect of JAK Inhibitors on Release of CXCL9, CXCL10 and CXCL11 from Human Airway Epithelial Cells

Tofacitinib

(2014) Deepti Vyas et al.   ANNALS OF PHARMACOTHERAPY

Non-invasive biomarkers in exacerbations of obstructive lung disease

(2013) Geoffrey Warwick et al.   RESPIROLOGY

CXCR3 ligands: redundant, collaborative and antagonistic functions

(2011) Joanna R Groom et al.   IMMUNOLOGY AND CELL BIOLOGY

New insights into the immunology of chronic obstructive pulmonary disease

(2011) Guy G Brusselle et al.   LANCET

Reduced apoptosis of CD8+ T-Lymphocytes in the airways of smokers with mild/moderate COPD

(2011) Liboria Siena et al.   RESPIRATORY MEDICINE

The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment

(2010) A. J. Steele et al.   BLOOD

TNFα and IFNγ Synergistically Enhance Transcriptional Activation ofCXCL10in Human Airway Smooth Muscle Cells via STAT-1, NF-κB, and the Transcriptional Coactivator CREB-binding Protein

(2010) Deborah L. Clarke et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Signal Transducer and Activator of Transcription-3, Inflammation, and Cancer

(2009) Bharat B. Aggarwal et al.   Annals of the New York Academy of Sciences

Serum IP-10 as a Biomarker of Human Rhinovirus Infection at Exacerbation of COPD

(2009) Jennifer K. Quint et al.   CHEST

Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune Diseases

(2009) Xiaoyu Hu et al.   IMMUNITY

Glucocorticoid resistance in inflammatory diseases

(2009) Peter J Barnes et al.   LANCET

IFNγ signaling—Does it mean JAK–STAT?

(2008) Daniel J. Gough et al.   CYTOKINE & GROWTH FACTOR REVIEWS

CXCR3 and CCR5 Chemokines in Induced Sputum From Patients With COPD

(2007) Claudia Costa et al.   CHEST